LDS/Medical Tests/miR-31now™ (microRNA) Colorectal Cancer Test

miR-31now™ (microRNA) Colorectal Cancer Test

Colorectal cancer (CRC) is the third most common cancer globally and the second leading cause of cancer-related mortality, with an estimated 1.93 million new cases and 935,000 deaths in 2020. Early-stage detection dramatically improves outcomes, with five-year survival rates exceeding 90% in stage I/II disease compared to just 14% in metastatic stage IVB/IVC. While colonoscopy remains the gold standard for CRC screening, its invasiveness, cost, and low compliance limit widespread use. Non-invasive tests such as CEA and CA19-9 offer limited sensitivity and specificity. There is growing interest in molecular biomarkers that can provide prognostic and predictive information beyond detection alone.

MicroRNAs (miRNAs) are small, non-coding RNAs that regulate post-transcriptional gene expression and play key roles in oncogenesis, immune response, apoptosis, and metastasis. Due to their stability in blood and other body fluids, they are attractive candidates for liquid biopsy applications.

The miR-31now™ assay measures expression of miR-31-3p, a validated microRNA biomarker associated with:

  • Tumor aggressiveness
  • Poor overall survival
  • Resistance to anti-EGFR therapies (e.g., cetuximab, panitumumab) in KRAS wild-type metastatic CRC

miR-31-3p overexpression has been linked to reduced response to EGFR-targeted therapy despite RAS wild-type status and may identify patients unlikely to benefit from such treatment, helping guide more personalized therapeutic strategies.

  • Prognostic stratification of colorectal cancer, particularly in stage II/III and metastatic settings
  • Prediction of resistance to anti-EGFR therapies (e.g., cetuximab, panitumumab)
  • Supportive decision-making in therapeutic planning and surveillance

Positive (High expression of miR-31-3p): Indicates higher tumor aggressiveness, poorer overall survival, and potential resistance to EGFR-targeted therapies in metastatic CRC. Suggests consideration of alternate treatment strategies.

Negative (Low or undetectable miR-31-3p): Suggests a better prognosis and higher likelihood of response to anti-EGFR therapy, especially in patients with RAS wild-type tumors.

Negative (Low or absent miR-31-3p expression)

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).

Whole blood, EDTA.

Stability

  • Ambient: 72 hrs.
  • Refrigerated: 7 days
  • Frozen: 15 days
Occult blood, CBC, Septin 9 methylation analysis, KRAS gene mutation analysis, BRAF gene mutation analysis, CEA, comprehensive metabolic panel, MSI Lynch Syndrome.
1- 2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login